Robert L. Talbert, Pharm.D., FCCP, BCPS
talbert@uthscsa.edu
|
Dr. Talbert is Professor of Pharmacy, College of Pharmacy with the
University of Texas at Austin and Head, Division of Pharmacotherapy. He
holds appointments as Professor of Medicine and Pharmacology at the University
of Texas Health Science Center in San Antonio. He received his Bachelor
of Science in Pharmacy (1971) and Doctor of Pharmacy (1974) degrees from
the University of Kentucky and completed a residency at the A.B. Chandler
Medical Center in Lexington, Ky. under the preceptorship of Dr. Paul Parker.
Dr. Talbert has authored more than 120 scientific and professional articles
and book chapters and is one of the editors of Pharmacotherapy: A Pathophysiology
Approach, now in the fourth edition. He has been the preceptor for more
than 30 specialty practice residents and five clinical sciences fellows.
He has served as major professor for five M.S. in Pharmacy students and
two of them have one best thesis awards on the University of Texas at
Austin campus.
Dr. Talbert has served American Society of Hospital Pharmacists as Chair
of the Special Interest Group in Adult Medicine and as a member of the
Commission on Therapeutics. He has served as Chair of the Section of Pharmacy
Practice for the American Association of Colleges of Pharmacy. He was
Chairman, Research Institute, American College of Clinical Pharmacy August
1993 - August 1994. Dr. Talbert has served as a member of the Specialty
Council on Pharmacotherapy of the Board of Pharmaceutical Specialties
and as a member of BPS for two terms. He is also Past-President of the
American College of Clinical Pharmacy (1992-1993) He has been a member
of the Advisory Panel on Cardiovascular and Renal Drugs, The United States
Pharmacopeial Convention (1992-1995) and was elected (1986) Fellow of
the American College of Clinical Pharmacy (FCCP). Dr. Talbert served on
the Board of Directors for Pharmacotherapy Publications, Inc for nine
years. He is a Board Certified Pharmacotherapy Specialist (Board of Pharmaceutical
Specialties). He has served a member of the American Heart Association
Committee on Scientific Sessions Planning since 2002.
He is responsible for didactic and clerkship teaching of baccalaureate
and Pharm. D. students and supervises their activities on the Medicine
Service at University Hospital in San Antonio. Dr. Talbert is a member
of the Drug Usage Committee and the Cardiovascular Subcommittee of the
Pharmacy and Therapeutics Committee for University Hospital. He was named
Preceptor of the Year in 2005. |
Publications (Since 2000)
Articles:
Talbert RL. Lipid management by pharmacists: evidence of benefits. Journal
of the American Pharmaceutical Association. 2000;40:143-4.
Talbert RL, Nappi JM. Combination antiplatelet therapy. U.S. Pharmacist 2000;25:86-98.
Crawford KM, Talbert RL. Antiplatelet therapy in secondary stroke prevention.
Expert Opinion in Pharmacotherapy 2001;2;1609-1613.
Talbert RL. Management of lipid disorders in the 21st century. Texas Pharmacy
Fall 2001:9-12.
Stringer KM, Lopez L, Talbert RL. A Call for Pharmacists to Improve the Care
of
Myocardial Infarction Patients. Pharmacotherapy 2001;21:1317-1319.
CTAP Consensus Panel Report and Scientific Roundtable. Acute Myocardial Infarction
and Ischemic Coronary Syndromes: Optimizing Selection of Reperfusion and Revascularization
Therapies in the Coronary Care Unit and Emergency Department. Hospital Pharmacists
Consensus Reports. 2001; December:1-24.
Nathisuwan S, Talbert RL. A review on vasopeptidase inhibitors: a new modality
in the
treatment of hypertension and congestive heart failure. Pharmacotherapy 2002;22:27-42.
Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA
reductase inhibitors, on fluconazole activity against Candida albicans. Journal
of Medical Microbiology. 2002:51:105-109.
Hawkins DW, Bradberry JC, Cziraky M, Talbert RL, Bartels D, Cerdeny J. NPCC
Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward
Better Patient Outcomes and New Roles for Pharmacists. Pharmacotherapy 2002;22:436-444.
Nappi JM, Talbert RL. Rationale for dual oral antiplatelet therapy to prevent
recurrent ischemic events. American Journal of Health-System Pharmacists 2002:59:1723-1735.
Koeller JM, Talbert RL. Modification of HDL-Cholesterol in the Management of
Cardiovascular Risk. Pharmacotherapy 2002;22:1266-1277.
Talbert RL, Spinler SA, Nappi JM, Bottorff M. Combination antiplatelet therapy:
Implications for pharmacists. Pharmacotherapy 2002:22:1211-1215.
Talbert RL. New therapeutic options in the National Cholesterol Education Program
Adult Treatment Panel III. American Journal of Managed Care 2002;8(suppl.):S301-S307.
Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E,
Sherman DG, Talbert RL, Marler JR. Lessons from the Stroke Prevention in Atrial
Fibrillation Trials. Annals of Internal Medicine 2003;138:831-838.
Hart RG, Leonard AD, Talbert, Rl, Pearce LA, Cornell E, Bovill E,, Feinberg
WM. Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease.
Pharmacotherapy 2003;23:579-584.
Recio V, Talbert RL. Low HDL-Cholesterol and the Risk of Heart Disease in Men.
Texas Pharmacy Spring 2003, p. 22-25.
Frei CR, Koeller, JM, Burgess, DS, Talbert, RL, Johnsrud, MT . Impact of Antimicrobial
Therapy on Outcomes in Hospitalized Patients with Community-Acquired Pneumonia.
Pharmacotherapy 2003;23:1167-1174.
Talbert RL. Niacin in the Treatment of Dyslipidemia: Insight from ATP III. Introduction.
American Journal of Health-System Pharmacy 2003;60 (supplement ):S1-S2.
Talbert RL. Role of the National Cholesterol Education Program Adult Treatment
Panel III Guidelines in Managing Dyslipidemia. American Journal of Health-System
Pharmacy 2003;60 (supplement ):S3-S8.
Talbert RL Pieper JA, Ito MK. Niacin and the NCEP ATP III Guidelines: Case Studies.
American Journal of Health-System Pharmacy 2003;60 (supplement):S22-S24.
V. Mahaguna, R. L. Talbert, J. I. Peters, S. Adams, T. D. Reynolds, F. Y. W.
Lam, and R. O. Williams III, Influence of Hydroxypropyl Methycellulose Polymer
on In Vitro and In Vivo Performance of Controlled Release Tablets Containing
Alprazolam, European Journal of Pharmaceutics and Biopharmaceutics 2003;56:461-468.
Feldman AM, Giles TD, Pina IL, Talbert RL. Clinical Trials of Beta Blockers
for Heart Failure: Questions and Controversies. Cardiology Review November 2003.
Talbert RL. Current Recommendations for the Treatment of Dyslipidemia. Pharmacy
and Therapeutics 2004;29:104-112.
Bauman JL, Talbert RL. Pharmacodynamics of Beta-Blockers in Heart Failure: Lessons
from the Carvedilol or Metoprolol European Trial. Journal of Cardiovascular
Pharmacology and Therapeutics 2004;9:1-12.
Bristow MR, Adams KF Jr., Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann
DL, Talbert RL. Roundtable Discussion. The COMET Trial. Congestive Heart Failure
2005;11(1):39-47.
McKenney JM, Bradberry JC, Talbert RL, Cahill E, Brown VW. A national survey
of pharmacists about coronary heart disease, high blood cholesterol, OTC statin
therapy and pharmacists’ services. Journal of the American Pharmacists
Association. 2004;44:562-568.
Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart
failure. Heart Failure Reviews 2004;9:131-137.
McConville JT, Carvalho TC, Iberg AN, Talbert RL, Burgess DS, Peters JI, Johnston
KP, Williams III RO. Design and Evaluation of a Restraint-Free Small Animal
Inhalation Dosing Chamber, Drug Development and Industrial Pharmacy, 1(2005)
35-42.
McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Hoeben BJ, Frei BL, Burgess
DS, Talbert RL, Peters JI, Johnston KP, Williams III RO. Novel Treatment using
Itraconazole Delivered via the Pulmonary Route and Enhanced Survival Following
Invasive Pulmonary Aspergillosis in the Murine Model – Submitted to legal
for intellectual property clearance.
Martin C, Talbert RL. Aspirin resistance. An evaluation of current evidence
and measurement methods. Pharmacotherapy 2005;25:942-953.
Books:
Pharmacotherapy: A Pathophysiologic Approach, 6th Edition, DiPiro JT, Talbert
RL,, Yee GC, Matzke GR, Wells BG and Posey LM (eds), McGraw-Hill Publishing,
Inc., New York, NY. 2005. (Section Editor - Cardiovascular Disorders pp. 149-494,
Respiratory Disorders pp. 495-604, Endocrine Disorders pp. 1333-1424.
Book Chapters:
Talbert RL, Bertin RJ. Chapter 120. Specialization in Pharmacy. In Remington:
The Science and Practice of Pharmacy, 21st Edition, Popovich, N (eds), Advanced
Concepts Institute, University of the Sciences in Philadelphia, Philadelphia,
PA. 2005, pp. 2155–2162 .
Talbert RL. Cardiovascular Testing. In Pharmacotherapy: A Pathophysiologic Approach,
6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM
(eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. 149-190.
Talbert RL. Thyroid Disorders. In Pharmacotherapy: A Pathophysiologic Approach,
6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM
(eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. .1369-1390.
Talbert RL. Ischemic Heart Disease. In Pharmacotherapy: A Pathophysiologic Approach,
4th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM
(eds), McGraw-Hill Publishing, Inc., New York, NY. 2005. pp. 261-290.
Talbert RL. Hyperlipidemia. In Pharmacotherapy: A Pathophysiologic Approach,
6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and Posey LM
(eds), McGraw-Hill Publishing, Inc., New York, NY. 2005, pp. 429-454.
Hoeben BJ, Talbert RL. Peripheral Vascular Disease. In Pharmacotherapy: A Pathophysiologic
Approach, 6th Edition, DiPiro JT, Talbert RL, Wells BG, Yee GC, Matzke G and
Posey LM (eds), McGraw-Hill Publishing, Inc., 2005, pp. 453-460.
Abstracts:
Nash JD, Burgess DS, Talbert RL. Effect of HMG CoA reductase inhibitors on fluconazole
activity against Candida albicans. Pharmacotherapy 2000;20:370.
Pace IP, Talbert RL, Trice S. Cost-efficacy analysis of influenza vaccination
versus neuriaminidase inhibitors. International Pharmaceutical Abstracts 2000;37:810.
Talbert RL. Evolution of thrombolytic therapy from infusion to bolus and combination
with IIb/IIIa receptor antagonists. International Pharmaceutical Abstracts 2000;37:801.
Raehl CL, Talbert RL, Bottorff M, MacLaughlin EJ. Heart Failure Care: Room for
a Pharmacist. ASHP Midyear Clinical Meeting. 2000;35(Dec):p PI-5.
Talbert RL, Raehl CL, Bottorff MD, MacLaughlin EJ. Heart failure care and background
therapy. ASHP Midyear Clinical Meeting. 35(Dec):pPI-5, 2000.
Talbert RL. Evolution of thrombolytic therapy from infusion to bolus and combination
with IIb/IIIa recetpro antagonists. ASHP Annual Meeting. 57(Jun):pPI-58, 2000.
Williams RO, Mahaguna V, Lam YWF, Peters JI, Adams S, Reynolds TD, Talbert RL.
Formulation development and pharmacokinetic study of alprazolam contained in
HPMC controlled release tablets. Pharmaceutical Research 2001; (accepted).
Talbert RL, Mahaguna V, Peters JI, Adams S, Reynolds TD, Williams RO III, Lam
YWF. Pharmacodynamics of alprazolam formulated in HPMC controlled release tablets.
Pharmaceutical Research 2001; (accepted).
Nathisuwan S, Talbert RL. Adherence to acute myocardial infarction treatment
guidelines and clinical outcomes. Pharmacotherapy 2001;21:1260.
Frei BL, Frei CR, Talbert RL. Evaluation of Perioperative b-Blocker Use for
the Prevention of Cardiovascular Complications in Elective, Noncardiac Surgery.
Pharmacotherapy 2002;22:1328.
Frei BL, Frie CL, Talbert RL. Evaluation of ACE inhibitiors for the prevention
of cardiovascular complications and death after elective, noncardiac surgery.
Pharmacotherapy 2003;23:393-394.
Benavente O, Hart R, Palacio S, Pearce L, Roldon A, Talbert R, Bazan C, Shepherd
A. Secondary Prevention of Small Subcortical Stroke (SPS3) Pilot Trial: Final
Results. Stroke (submitted).
Shepherd, AMM, Roldan A, Palacio S, Benavente O, Hart R, Williams L, Holliday,
S Talbert, RL, Roman G, Sherman D, Pearce L. Blood pressure results from the
SPS3 pilot study. American Journal of Hypertension (submitted).
Lopez TC, Rascati KL, Young VS, Knodel LC, Talbert RL. Incidence of antidiabetic
medication use following atypical antipsychotic use in a Texas Medicaid population.
Pharmacotherapy 2003;23:#244.
McConville JT, Overhoff KA, Prapasri S, Hoeben BJ, Frei BL, Burgess DS, Talbert
RL, Peters JI, Johnston KP, Williams RO III. Delivery of Poorly Water Soluble
Drugs using Nebulization, Proceedings of the 15th Drug Delivery to the Lung
Conference, London, United Kingdom, 2004.
Hoeben BJ, Burgess DS, Najvar LK, Talbert RL, McConville JT, Peters JI, Graybill
JR, Jones, BL, Wiederhold NP, Williams RO. In vivo efficancy of aerosolized
nanostructure itraconazole (ITR) formuations for the prevention of invasive
pulmonary aspergillosis (IPA). ICAAC (submitted)
Hoeben BJ, D.S. Burgess DS, Najvar LK, Talbert RL, McConville JT, .Peters JI,
, R. Bocanegra R, Graybill JR, ,Jones BL, Wiederhold NP, Williams RO III.. In
vivo Efficacy of Aerosolized Nano-structured Itraconazole (ITZ) Formulations
for the Prevention of Invasive Pulmonary Aspergillosis (IPA) ICAAC (submitted)
Return to Faculty Directory
UT Home Page |
Pharmacy Home Page |
Pharmacotherapy Home Page